Tag: Glas

  • FDA Memo Questions Flavored-Vape Reversal: AP  

    FDA Memo Questions Flavored-Vape Reversal: AP  

    A newly released FDA memo is raising questions about the agency’s watershed authorization of fruit-flavored e-cigarettes after revealing that the products were not significantly more effective at helping smokers quit than tobacco-flavored alternatives, according to the Associated Press. The decision drew criticism from public health groups and Democratic lawmakers, who argue the authorization departs from the agency’s long-standing position that fruit and dessert flavors require a particularly high evidentiary standard because of their appeal to youth.

    The six-page document, published weeks after the FDA approved mango- and blueberry-flavored vaping products from Glas Inc., acknowledged that study data showed no statistically significant difference in smoking cessation outcomes between users of the fruit-flavored products and those using tobacco-flavored e-cigarettes. The finding contrasts with previous FDA authorizations of flavored products, including menthol e-cigarettes from Juul Labs and NJOY, which demonstrated measurable benefits over tobacco-flavored products.

    However, the AP said regulators explained that the Glas flavored vapes “did not have to demonstrate added adult benefit,” because young people were unlikely to use them. Glas requires users to unlock each e-cigarette with an age-verifying cellphone app. The memo indicates that FDA regulators instead relied heavily on the company’s age-verification technology, concluding that youth uptake was unlikely because users must unlock devices through a smartphone app.  The approval was finalized shortly before the departure of former FDA Commissioner Marty Makary and comes amid broader scrutiny of the agency’s recent approach to vaping regulation.

  • BAT Stock Surges, Despite Legacy Combustibles Shrinking

    BAT Stock Surges, Despite Legacy Combustibles Shrinking

    Shares of British American Tobacco climbed 13.99% in London trading last week to £48.64 on May 15, as investors reacted to a mix of regulatory, legal, and capital signals. Market attention followed the U.S. Food and Drug Administration authorization of flavored Glas ENDS products, seen as a reference point for how flavored e-cigarettes may fare under the PMTA pathway, even though the decision did not involve BAT’s Vuse brand. Sentiment was further supported after a U.S. court dismissed a sanctions-related criminal case tied to BAT’s prior North Korea compliance matter, confirming the company had fulfilled its deferred prosecution agreement, alongside continued focus on BAT’s planned £1.3 billion 2026 share buyback and growth prospects for its newer nicotine portfolio, including VELO.

    In contrast, BAT Bangladesh reported a 14% year-on-year drop in cigarette volumes and a 34% decline in profit for Q1 2026 amid higher taxes, inflationary pressure, and weaker consumer purchasing power, underscoring the diverging performance between BAT’s legacy combustible markets and investor expectations tied to reduced-risk product expansion.

  • FDA Authorizes Four New ENDS Products

    FDA Authorizes Four New ENDS Products

    The U.S. Food and Drug Administration has authorized four Glas electronic nicotine delivery system products through the PMTA pathway, including Classic Menthol, Fresh Menthol, Gold, and Sapphire pods containing 5% nicotine. The decision marks the first FDA authorization of ENDS products beyond traditional tobacco and menthol flavors, expanding the range of legally marketed vaping products in the U.S. to 45.

    The agency said the authorization was based on evidence that the products’ device access restriction technology—requiring age verification via government ID, smartphone pairing, and biometric checks—can effectively limit youth access.

    “By helping to prevent youth use, device access restrictions are a potential game changer,” said Dr. Bret Koplow, acting director of the FDA’s Center for Tobacco Products. “This technology is also an indication of the role innovation may serve in the effort to protect young people from threats posed by nicotine use and addiction while helping to enable [the] availability of an expanded array of flavored options for adults who smoke who may use these products to completely switch away from regular cigarettes.”

    The FDA emphasized that marketing must be targeted to adults and that the company must monitor and report on youth prevention measures, while noting that authorization could be withdrawn if compliance requirements are not met or if youth usage increases.